Systems Biology in Drug Discovery and Development - edition reliée, livre de poche

EAN (ISBN-13): 9780470261231
ISBN (ISBN-10): 0470261234
Version reliée
Date de parution: 20120615
Editeur: Wiley
376 Pages
Poids: 0,697 kg
Langue: Englisch

Livre dans la base de données depuis 2011-04-04T02:30:51+02:00 (Paris)
Page de détail modifiée en dernier sur 2023-07-26T12:40:28+02:00 (Paris)
ISBN/EAN: 9780470261231

ISBN - Autres types d'écriture:
0-470-26123-4, 978-0-470-26123-1
Autres types d'écriture et termes associés:
Auteur du livre: seth, michels, john young, michelson
Titre du livre: development, discovery, seth buch, systems biology, systems art

---

Données de l'éditeur

Auteur: Daniel L. Young; Seth Michelson
Titre: Wiley Series on Technologies for the Pharmaceutical; Systems Biology in Drug Discovery and Development
Editeur: John Wiley & Sons
376 Pages
Date de parution: 2011-11-18
Poids: 0,693 kg
Langue: Anglais
112,00 € (DE)
No longer receiving updates
163mm x 235mm x 26mm

BB; gebunden; Hardcover, Softcover / Chemie; Medizinische Chemie, Pharmazeutische Chemie; Drug Discovery & Development; Bioinformatik; Bioinformatik u. Computersimulationen in der Biowissenschaften; Pharmazeutische Chemie; Life Sciences; Biowissenschaften; Pharmakologie u. Pharmazeutische Medizin; Wirkstoffforschung; Pharmacology & Pharmaceutical Medicine; Wirkstoffforschung u. -entwicklung; Medical Science; Bioinformatics & Computational Biology; Chemie; Medizin; Chemistry; Wirkstoffforschung u. -entwicklung; Pharmakologie u. Pharmazeutische Medizin; Bioinformatik u. Computersimulationen in der Biowissenschaften

Part I: Introduction to Systems Biology Approach. Chapter 1. Introduction to systems biology in drug discovery and development. 1.1 Introduction. Chapter 2. Methods for In Silico Biology: Model Construction and Analysis. 2.1 Introduction. 2.2 Model building. 2.3 Parameter estimation. 2.4. Model analysis. 2.5 Conclusions. Chapter 3. Methods in In Silico Biology: Modeling Feedback Dynamics in Pathways. 3.1 Introduction. 3.2 Statistical modeling. 3.3 Mathematical modeling. 3.4 Feedback and feedforward. 3.5 Conclusions. Chapter 4. Simulation of Population Variability in Pharmacokinetics. 4.1 Introduction. 4.2 PBPK modeling. 4.3 Simulation of pharmacokinetic variability. 4.4 Conclusions and future directions. Part II: Applications to Drug Discovery. Chapter 5. Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery. 5.1 Introduction. 5.2 Typical drug discovery paradigm. 5.3 Integrated drug discovery. 5.4 Drivers of the disease phenotype: clinical endpoints and hypotheses. 5.5 Extracellular disease drivers: mechanistic biotherapeutic models. 5.6 Relevant cell models for clinical endpoints. 5.7 Intracellular disease drivers: signaling pathway quantification. 5.8 Target selection: dynamic pathway modeling. 5.9 Conclusions. Chapter 6. Lead Identification and Optimization. 6.1 Introduction. 6.2 The systems biology toolkit. 6.3 Conclusions. Chapter 7. The role of core biological motifs in dose-response modeling: an example with switch-like circuits. 7.1 Introduction: systems perspective in drug discovery. 7.2 Systems biology and toxicology. 7.3 Mechanistic/computational concepts in a molecular/cellular context. 7.4 Response motifs in cell signaling and their role in dose response. 7.5 Discussion and conclusions. Chapter 8. Mechanism Based Pharmacokinetic-Pharmacodynamic Modeling During Discovery and Early Development. 8.1 Introduction. 8.2 Challenges in drug discovery and development: the need to bring together PK and PD. 8.3 Methodological aspects and concepts. 8.4 Application during lead optimization. 8.5 Application during clinical candidate selection. 8.6 Entry into human (EIH) preparation and translational PK/PD modeling. 8.7 PK/PD for toxicology study design and evaluation. 8.8 Justification of starting dose, calculation of safety margins, and support of phase I design. 8.9 Phase I and beyond. 8.10 Support of early formulation development. 8.11 Outlook and conclusions. Part III: Applications to Drug Development. Chapter 9. Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases. 9.1 Introduction. 9.2 Modeling angiogenesis. 9.3 Use of rigorous mathematical analysis for gaining insight on drug development. 9.4 Use of angiogenesis models in theranostics. 9.5 Use of angiogenesis models in drug salvage: the virtual patient technology. 9.6 Summary and conclusions. Chapter 10. Systems Modeling Applied to Candidate Biomarker Identification. 10.1 Introduction. 10.2 Biomarker discovery approaches. 10.3 Examples of systems modeling approaches for identification of candidate biomarkers. 10.4 Conclusions. Chapter 11. Simulating Clinical Trials. 11.1 Introduction. 11.2 Types of models used in clinical trial design. 11.3 Sources of prior information for designing clinical trials. 11.4 Aspects of a trial to be designed and optimized. 11.5 Trial simulation. 11.6 Optimizing designs. 11.7 Real world examples. 11.8 Conclusions. Part IV: Synergies with other technologies. Chapter 12. Pathway Analysis in Drug Discovery. 12.1 Introduction: pathway analysis, dynamic modeling, and network analysis. 12.2 Software systems for pathway analysis. 12.3 Pathway analysis in modern drug development pipeline. 12.4 Conclusions. Chapter 13. Functional mapping for predicting drug response and enabling personalized medicine. 13.1 Introduction. 13.2 Functional mapping. 13.3 Predictive modeling. 13.4 Future directions. Chapter 14. Future Outlook of Systems Biology. 14.1 Introduction. 14.2 Systems complexity in biological systems. 14.3 Models for quantitative integration of data. 14.4 Changing requirements for systems approaches during drug discovery and development. 14.5 Better models for better decisions. 14.6 Advancing personalized medicine. 14.7 Improving clinical trials and enabling more complex treatment approaches. 14.8 Collaboration and training for systems biologists. 14.9 Conclusions.